Down-regulation of LPCAT expression increases platelet-activating factor level in cirrhotic rat liver: Potential antiinflammatory effect of silybin  by Stanca, Eleonora et al.
Biochimica et Biophysica Acta 1832 (2013) 2019–2026
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isDown-regulation of LPCAT expression increases platelet-activating
factor level in cirrhotic rat liver: Potential antiinﬂammatory effect
of silybinEleonora Stanca a, Gaetano Serviddio b, Francesco Bellanti b, Gianluigi Vendemiale b,
Luisa Siculella a, Anna Maria Giudetti a,⁎
a Laboratory of Biochemistry and Molecular Biology, Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy
b Department of Medical and Surgical Sciences, University of Foggia, Italy⁎ Corresponding author at: Department of Biological a
Technologies, Via Monteroni, University of Salento, 7
832298679.
E-mail address: anna.giudetti@unisalento.it (A.M. Gi
0925-4439/$ – see front matter © 2013 Elsevier B.V. All
http://dx.doi.org/10.1016/j.bbadis.2013.07.005a b s t r a c ta r t i c l e i n f oArticle history:
Received 20 February 2013
Received in revised form 24 June 2013
Accepted 3 July 2013
Available online 12 July 2013
Keywords:
Biliary cirrhosis
Lysophosphatidylcholine acyltransferase
Platelet-activating factor
SilybinCholestasis is one of the major causes of liver diseases. A chronic accumulation of toxic bile acids in the liver,
which occurs in this condition, can induce ﬁbrosis and cirrhosis. Inﬂammation is a fundamental component of
acute and chronic cholestatic liver injury.
Platelet-activating factor (PAF) is a proinﬂammatory lipid which may be generated by two independent path-
ways called the de novo and remodeling pathway being the last responsible for the synthesis of PAF during
inﬂammation. In recent years a key role in PAF remodeling has been attributed to lysophosphatidylcholine
acyltransferase (LPCAT) enzymes. Although the knowledge on their characteristic is growing, the exact
mechanism of LPCAT in pathological conditions remains still unknown.
Here, we reported that the level of lyso-PAF and PAF signiﬁcantly increased in the liver of cirrhotic vs. control
rats together with a signiﬁcant decrease in both mRNA abundance and protein level of both LPCAT1 and
LPCAT2. Acyltransferase activities of both LPCAT1 and LPCAT2 were parallel decreased in the liver of cirrhotic
animals. Interestingly, treatment with silybin strongly decreased the level of both pro-inﬂammatory lipids
and restored the activity and expression of both LPCAT1 and LPCAT2 of cirrhotic liver. Silybin effect was spe-
ciﬁc for LPCAT1 and LPCAT2 since it did not affect LPCAT3 mRNA abundance of cirrhotic liver.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cholestasis is a pathological condition caused by injury to the bile
ducts induced by immunologic, toxic, or genetic causes [1]. Cholesta-
sis results in intrahepatic accumulation of potentially toxic bile acids
leading to hepatocyte apoptosis and necrosis [1]. Moreover, the com-
bined effects of progressive inﬂammation and toxicity of bile trapped
within hepatocytes can culminate in cirrhosis [2]. Excessive bile accu-
mulation into the liver has been reported to markedly alter the ex-
pression of various genes involved in cholesterol and phospholipid
homeostasis [3].
Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine or PAF) and alkyl-lysophosphatidylcholine (lyso-PAF)
are phosphatidylcholine-derived molecules with important roles in
inﬂammatory processes [4]. It has been demonstrated that PAF and
lyso-PAF are hyper-produced in many inﬂammatory conditions such asnd Environmental Sciences and
3100 Lecce, Italy. Tel.: +39
udetti).
rights reserved.diabetes [5] and nervous system diseases [6] where they activate inﬂam-
matory process and oxidative stress.
Recently, several observations have indicated increased plasma [9]
and liver [10] PAF levels in cirrhotic rats suggesting a crucial role of
PAF in liver diseases progression [7–9].
PAF can be synthesized through two different pathways: the de
novo and a recovery pathway [4]. The latter involves the hydrolysis
of alkyl-PC at sn-2 position by PLA2 with the production of lyso-PAF
which can be acetylated, in presence of acetyl-CoA, in a reaction cat-
alyzed by the key enzyme lyso-PAF:acetyl-CoA acetyltransferase
(PAF-AT, EC 2.3.1.67) [11]. While the de novo synthesis is linked to
a constitutive production of PAF, the remodeling pathway seems to
be involved in inﬂammatory responses of PAF [12]. Interestingly,
the two biosynthetic pathways are associated to distinct activities
thus allowing targeting antiinﬂammatory intervention to speciﬁc en-
zymes [13].
The catabolism of PAF is normally made by PAF-acetylhydrolases
(PAF-AH) which catalyze the degradation of PAF during antiinﬂam-
matory response [14]. In fact, treatment of diabetic rats with recombi-
nant PAF-AH reduces insulitis and the frequency of diabetes [15].
In addition to the well characterized PAF-AT and PAF-AH, a grow-
ing number of enzymes have been recognized, in the last few years, in
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lysophosphatidylcholine acyltransferases (LPCAT 1–4) are now consid-
ered to be involved in PAF remodeling during inﬂammation [16–20].
Although a signiﬁcant progress has been made in the study of
LPCAT enzymes, their role in pathological conditions remains still
unknown.
Aim of the present study was to investigate the role of LPCATs in a
rodent model of secondary biliary cirrhosis. The effect of silybin, a
well known hepatoprotective compound [21–23] on the activity and
expression of LPCAT was also evaluated.
The most relevant results were that the level of proinﬂammatory
lyso-PAF and PAF dramatically increased and the mRNA expression of
LPCAT1, LPCAT2 and LPCAT3 signiﬁcantly reduced in the liver of cirrhot-
ic rats. Silybin was able to restore normal level of inﬂammatory lipids
and to normalize gene expression of both LPCAT1 and LPCAT2 but not
LPCAT3. A role for LPCAT1 and LPCAT2 in the antiinﬂammatory effect
of silybin, in the liver, was then discussed.
2. Materials and methods
2.1. Materials
All lipids, acyl-CoAs, 4-amidinophenylmethanesulfonyl ﬂuoride
(APMSF), 7-diethylaminocoumarin-3-carbonylazide, 7-methoxycou-
marin-4-acetic acid, 1,2-dimethoxyethane, N,N′-dicyclohexyl-
carbodiimide, phospholipase C (Bacillus cereus, type IXV) were
purchased from Sigma. [14C]acetyl-CoA, [14C]oleoyl-CoA, [14C]palmitoyl-
CoA and [14C]arachidonyl-CoA were supplied by PerkinElmer
(PerkinElmer, Monza, Italy). 4N3OBA was from Vinci-Biochem s.r.l.,
LPCAT2 and LPCAT1 antibodies were from DBA Italy s.r.l. RNAlater solu-
tion and SV Total RNA Isolation Systemkit fromPromega. SuperScriptTM
III RNase H-Reverse transcriptase was from Invitrogen. Primers were
purchased from Sigma. All other chemicals and reagents were of analyt-
ical grade.
2.2. Animal model
Male Wistar rats, weighing 200–250 g, supplied by Harlan Italy Srl
(S. Pietro al Natisone, UD), housed at 22 ± 1 °C, have been used
throughout the study. The animals were maintained and sacriﬁced
according to the Italian Ofﬁcial Statement N.116/92. The animals
were divided into three groups: a group of rats subjected to bile
duct ligation (BDL), a group of control rats (SHAM), subjected to the
entire surgical procedure except for the ligation, and ﬁnally a group
of BDL rats treated with silybin (BDL + Sil). The duct ligation was
performed as previously described by Serviddio et al. [1]. The induc-
tion of chronic cholestasis was demonstrated by increases in the con-
centration of bilirubin in the serum of rats BDL which was found
7.3 ± 3.3 mg/dl vs. 0.5 ± 0.3 mg/dl of the controls (Fig. 1). Histolog-
ical analysis after 4 weeks of bile duct ligation in rats BDL shows that
the liver developed the characteristic of liver cirrhosis, with an inho-
mogeneous structure due to the presence of ﬁbrous septa highlighted
by Masson's trichrome (Fig. 1).
2.3. Histological analysis
Small blocks of liver tissue from all mice were immediately ﬁxed
in 4% neutral formalin and embedded in parafﬁn. Sections (4 μm
thick) were stained by the hematoxylin and eosin or Masson's
trichrome method. At least three discontinuous liver sections were
evaluated for each mouse.
2.4. Biochemical analysis
Serum activities of aspartate aminotransferase (AST), alanine ami-
notransferase (ALT) and alkaline phosphatase (ALP) were measuredwith AST, ALT and ALP assay kits, respectively (Catachem, Bridgeport,
CT).
2.5. Isolation of microsomal fraction from rat liver
For microsome isolation liver were homogenized in a cold buffer
containing 100 mM Tris–HCl (pH 7,4), 250 mM sucrose, 5 mM
2-mercaptoethanol, 20 μM 4-APMSF and a cocktail of protease inhibi-
tors as reported in [17].Microsomeswere isolated by differential centri-
fugation as reported in [24].
2.6. Phospholipase A2 activity
Phospholipase A2 (PLA2) activity was assayed as reported in [25] in
liver homogenates by using 4N3OBA as substrate. Reaction mixture
contained 150 mM KCl, 10 mM CaCl2, 50 mM Tris–HCl, pH 7.5 and
4N3OBA 2 mM. The reaction was started by addition of samples and
after 1 h, at room temperature; the absorbance was read at two differ-
entwavelengths (425 nmand 600 nm to correct for any turbidity in the
sample). Speciﬁc activity was expressed as μmol/h × mg protein.
2.7. Assay of lyso-PAF acyltransferase activity
The acyltransferase activity of LPCAT1 was assayed essentially as re-
ported in [18]. Brieﬂy, 5 μg ofmicrosomal fractionswas used to start the
reaction in an assay mix containing 100 mM Tris–HCl (pH 7.4), 1 mM
EDTA, 1 mg/ml PC, 20 μM lyso-PAF (1-O-palmityl-sn-glycero-3-
phosphocholine), 25 μM [14C]oleoyl-CoA (2.035 GBq/mmol) or 25 μM
[14C]palmitoyl-CoA (293 MBq/mmol). After 5 min at 30 °C reaction
was stopped adding 600 μl of a cold mixture of chloroform/methanol
1:2 (v/v). LPCAT2 acyltransferase activity wasmeasured as in [19] incu-
bating 5 μg of microsomal proteins in a buffer containing 20 mM Tris–
HCl (pH 7.4), 2 mM CaCl2, 1 mg/ml PC, 20 μM APMSF, 5 mM
2-mercaptoethanol, 20 μM lyso-PAF (1-O-palmityl-sn-glycero-3-
phosphocholine) and 20 μM [14C]arachidonyl-CoA (1.11–2.035 GBq/
mmol). After 10 min at 37 °C reaction was stopped adding 600 μl of a
cold mixture of chloroform/methanol 1:2 (v/v). After extraction, lipids
were separated by thin layer chromatography. Bands at positions corre-
sponding to expected productwere scraped from the plate and radioac-
tivity counted using liquid scintillation.
2.8. Assay of LPCAT1 and LPCAT2 acetyltransferase activities
Both LPCAT1 and LPCAT2 have been demonstrated to catalyze
acetyltransferase reaction [26]. The acetyltransferase activity of
LPCAT1was assayed as reported in [17]. Brieﬂy, 5 μg ofmicrosomal pro-
tein was incubated in a buffer containing 20 mM Tris–HCl (pH 7.4),
5 mM 2-mercaptoethanol, 20 μM APMSF, 1 mg/ml PC, 1 mM EDTA,
20 μM lyso-PAF and 200 μM [3H]acetyl-CoA. Acetyltransferase activity
of LPCAT2 was assayed following the procedure described in [17]. In
this case microsomal proteins were incubated in a buffer containing
20 mM Tris–HCl (pH 7.4), 5 mM 2-mercaptoethanol, 20 μM APMSF,
1 mg/ml PC, 2 mM CaCl2, 20 μM lyso-PAF and 100 μM [3H]acetyl-CoA.
After 10 min at 37 °C reactions were stopped by chloroform/methanol
1:2 (v/v). After lipid extraction and separation by TLC radioactivity asso-
ciated to the radiolabeled productswasmeasured by liquid scintillation.
2.9. Assay of liver lyso-PAF acetyltransferase activity
We also assayed the lyso-PAF acetyltransferase activity as in [27].
In this case, 50 μg of liver homogenate was incubated in a buffer con-
taining 250 mM Tris–HCl, 25 mM BSA at pH 6.9 in presence of 20 μM
[14C]acetyl-CoA and 20 μM lyso-PAF. Reaction lasted 20 min at 37 °C
and was terminated by adding chloroform/methanol 1:2 (v/v). Lipid
extracted was loaded on TLC plate and after separation the band
Fig. 1. Panel A: histological analysis of liver specimens stained with haematoxylin and eosin (HE) or Masson trichrome (MT) from the same experimental groups (original magni-
ﬁcation, 100×). Panel B: serum aspartate and alanine aminotransferases (AST, ALT) and alkaline phosphatase (AP) levels in rats undergoing sham operation (SHAM), bile duct ligation
(BDL) and BDL fed a diet containing silybin (BDL + Sil) 21 days after bile duct ligation. Data are expressed as means ± SD of ﬁve experiments for each group.
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scraped and radioactivity was counted by liquid scintillation.2.10. TLC analysis of lipids
Total lipids were extracted using the Bligh-Dyer procedure [28]
and separated by TLC. The mobile phase was represented by
chloroform/methanol/water (65:25:4, v/v/v). At the end of the
lipid separation bands corresponding to different lipids were identi-
ﬁed by comparison with known lipids.2.11. HPLC separation and quantiﬁcation of PAF and lyso-PAF
Lyso-PAF amountwas quantiﬁed as reported in [29]. After tissue ho-
mogenization, lipidswere extracted by chloroform/methanol (1:2, v/v).
2-lysophospholipid species were derivatized with 100 μl of 1 mg/ml
solution of 7-diethylaminocoumarin-3-carbonylazide in anhydrous
toluene. After 3 h at 80 °C the vials were cooled and ﬂuorescent deriv-
atives were analyzed by HPLC using a C18 reversed-phase column
(Phenomenex). The elution was performed with a gradient of solvent
A (methanol–water, 80:20, v/v, containing 250 mg/l choline chloride)
and solvent B (chloroform) at a ﬂow-rate of 1.0 ml/min. Detection
Fig. 2. Lyso-PAF and PAF liver levels. Total lipids were extracted from liver of control
(SHAM), cirrhotic (BDL) and BDL rats treated with silybin (BDL + Sil). After separation
by HPLC and ﬂuorimetric detection, lyso-PAF (A) and PAF (B) were quantiﬁed compar-
ing the area value of identiﬁed peaks with that of known amount of standards. Data are
the means ± SD of three different experiments for each group. Statistical differences
were assessed using Student's t test.
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480 nm).
PAFwas quantiﬁed following themethod reported in [30]. Brieﬂy,
extracted lipids were hydrolyzed by phospholipase C. The hydro-
lyzed products were derivatizated overnight at 4 °C in presence
of 7-methoxycoumarin-4-acetic acid, 1,2-dimethoxyethane and
N,N′-dicyclohexylcarbodiimide. Derivatives were separated by
HPLC using a C18 reverse-phase column (Phenomenex) by isocratic
elutionwith 90%methanol at 1 ml/min. Fluorescence wasmonitored
at 330 nm excitation and 415 nm emission wavelengths.
Lyso-PAF and PAF amount were evaluated by comparing peak area
of unknown samples with that of known amount of lyso-PAF or PAF.
2.12. Reverse transcriptase and Real-time PCR
A piece of the liver was dissected out and collected in RNAlater Solu-
tion for RNA extraction. Total RNA was extracted from 0.3 g of tissue
using the SV Total RNA Isolation System kit following the
manufacturer's protocol. Only RNA without DNA contamination was
used for subsequent preparation of cDNA synthesis. The RT (reverse
transcriptase) reaction (20 μl) was carried out using 5 μg of total RNA,
100 ng of random hexamers and 200 units of SuperScriptTM III RNase
H-Reverse transcriptase. Quantitative gene expression analysis was
performed (SmartCycler System, Cepheid) using SYBR Green technolo-
gy (FluoCycle, Euroclone). The sequences of primers used in Real-time
PCR were the following: Lpcat1 forward: 5′-gACCCTCgAgTgATgTAA
CC-3′ and Lpcat1 reverse: 5′-gATggATgCAgATTTCTAAC-3′ (GenBank™
accession number NM_001100735.1); Lpcat2 forward 5′-ATTATTCTg
CTTCCAgTCCg-3′, Lpcat2 reverse 5′-AgAAgAACATggCACgACC-3′
(Gen-Bank™ accession number XM_001064713); and Lpcat3 forward
5′-TTgCTTCCAgATggCCTAC-3′, Lpcat3 reverse 5′-ATgAggggACACCCA
GTATg-3′ (Gen-Bank™ accession number NM_001012189). Rplp0 was
used as an internal control for normalization [2].
2.13. Western blot analysis
Microsomal proteins were loaded onto 12% SDS-PAGE gel and
transferred to nitrocellulose membrane for immunoblot analysis
with anti-LPCAT1 and LPCAT2 antibodies at room temperature for
2 h, then membrane was incubated for 1 h with secondary horserad-
ish peroxidase-conjugated IgG (dilution, 1:2000). Signals were de-
tected by enhanced chemiluminescence. For signal normalization,
alpha-tubulin was used. The intensity band was evaluated densitom-
etry with Molecular Analyst Software.
2.14. Statistical analysis
Data were expressed as means ± standard deviation (SD). The
unpaired t test was used to verify the signiﬁcance of differences be-
tween means. In all instances P b 0.05 was taken as the lowest level
of signiﬁcance. The GraphPad Prism 4 for Windows (GraphPad Soft-
ware Inc., San Diego, CA, USA) was used to perform all the analyses.
3. Results
3.1. Liver histology and biochemical analysis
Serum AST, ALT, ALP and bilirubin levels were measured together
with liver histology and the results are reported in Fig. 1. Liver from
BDL group showed cholestasis and hepatocellular necrosis, as well
as extensive bile duct proliferation, neutrophils and lymphocytes in-
ﬁltration, and ﬁbrosis. Silybin signiﬁcantly reduced liver necrosis, in-
ﬂammation, ﬁbrosis and bile duct proliferation (Fig. 1A) as well as
serum cholestasis (Fig. 1B) as compared to sham rats.3.2. PAF and lyso-PAF level increased during cirrhosis
Inﬂammation plays a pivotal role in the pathophysiology of liver
cirrhosis [2]. The amount of proinﬂammatory PAF and its precursor
lyso-PAF was measured in the liver of sham and BDL animals. The
level of lyso-PAF (19.8 ± 1.4 pmol/mg protein in cirrhotic vs. 12 ±
1.0 pmol/mg protein in normal rats; P b 0.05, Fig. 2A) and PAF
(10.9 ± 1.1 fmol/mg protein in cirrhotic vs. 3.2 ± 0.8 fmol/mg pro-
tein in normal rats; P b 0.05, Fig. 2B) signiﬁcantly increased in the
liver of cirrhotic rats. The treatment with silybin signiﬁcantly re-
duced both the content of PAF and particularly of lyso-PAF (Fig. 2).
3.3. Activity of phospholipase A2 during cirrhosis
It has been demonstrated that PLA2 activity increases after several
inﬂammatory stimuli [31]. This enzyme accounts for the break of the
sn-2 bond in the phospholipids which generates lyso-PAF that, in
turn, can be utilized for PAF synthesis. We hypothesized that the in-
creased amount of PAF occurring in the liver of BDL animals was de-
pendent on the activation of PLA2. As expected, PLA2 activity was
signiﬁcantly increased (~140%) in cirrhotic liver, as compared to nor-
mal rats (Fig. 3). Once again, the administration of silybin was able to
reduce the PLA2 activity that, however, did not reach normal values.
3.4. Down-regulation of LPCAT gene and protein expression during
chronic cholestasis
LPCAT1, LPCAT2 and LPCAT3 mRNA abundance was measured in
liver from BDL and sham operated rat livers. As reported in Fig. 4,
mRNA of all LPCAT isoforms was reduced in the liver of BDL with re-
spect to sham rats. This was particularly evident for LPCAT1 and
LPCAT2 whose expression appeared almost completely suppressed
Fig. 3. Measurement of liver phospholipase A2 activity. PLA2 activity was measured in
liver homogenates from control (SHAM), cirrhotic (BDL) and BDL rats treatedwith silybin
(BDL + Sil). PLA2 activity is expressed as μmol/h × mg protein. Results reported in the
ﬁgure are the means ± SD of six independent experiments. Statistical differences were
assessed using Student's t test.
Fig. 4. LPCAT1, LPCAT2 and LPCAT3 mRNA abundance. Quantitative Real time PCR was
used to determine LPCAT1, LPCAT2, and LPCAT3 gene expression levels in the liver of
control (SHAM), cirrhotic (BDL) and cirrhotic rats treated with silybin (BDL + Sil).
mRNA content was normalized using Rplp0. Data shown are the means ± SD of four
different experiments.
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as compared to sham rats. Very interestingly, in silybin treated BDL
rats the expression of LPCAT1 and LPCAT2 was completely restored.
Of note, silybin did not impact the expression of LPCAT3. Taken to-
gether these results suggested a speciﬁc role for LPCAT1 and LPCAT2
in the modulation of liver PAF level during cirrhosis development.
Western blotting analysis conﬁrmed that inhibition of LPCAT oc-
curred also in terms of protein expression and that silybin was able
to restore physiological level of proteins (Fig. 5).
3.5. LPACT1 and LPCAT2 lyso-PAF acyltransferase activities
Since LPCAT1 has antiinﬂammatory properties by catalyzing the acyl-
ation of lyso-PAF to alkyl-PC [5] we verify the hypothesis that the higher
level of PAF observed in BDL animals, was due to a low acyltransferase
activity which give lyso-PAF more available for PAF synthesis. Both
[14C]palmitoyl-CoA and [14C]oleoyl-CoA were used as acyl-CoA donors
to assay acyltransferase activity of LPCAT1. We also measured the
acyltransferase activity of LPCAT2 using [14C]arachidonyl-CoA as sub-
strate. As reported in Fig. 6A, the acyltransferase activity of LPCAT1 was
higher in the controls when palmitoyl-CoA was used as a substrate as
compared to oleyl-CoA. When cholestatic livers were compared to
sham operated animals a signiﬁcant inhibition of the incorporation of
both fatty acids in lyso-PAFwas observed (Fig. 6A). The resultwas similar
when acyltransferase activity of LPCAT2wasmeasured in the presence of
[14C]arachidonyl-CoA (Fig. 6B). Once again, silybin was able to restore
normal conditions.
3.6. LPACT1 and LPCAT2 lyso-PAF acetyltransferase activities
Under inﬂammatory stimuli LPCAT2 may increase the rate of
acetyl-CoA incorporation into lyso-PAF to form PAF [18] whereas
LPCAT1 has been demonstrated to be involved in a non-inﬂammatory
synthesis of PAF [17]. LPCAT activity involved in PAF synthesis during
cirrhosis was assayed by using the method described in [17].
Acetyltransferase activity of LPCAT2 was hardly detected in all three
groups of rats whereas no activity of LPCAT1 was found (data nor
shown).
As a result we supposed that the increased level of PAF found in
the liver of BDL animals could be due to liver acetyltransferase activ-
ities not dependent on LPCAT enzymes. The acetyltransferase activity
was then measured in the whole liver homogenate using the method
reported in [27] and the results are reported in Fig. 7. The activity was
observed to be signiﬁcantly higher in BDL with respect to control rats
and not prevented by the administration of silybin.4. Discussion
Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-
phosphocholine or PAF) is a potent pro-inﬂammatory lipid mediator
which plays an important role in metabolic and pathologic changes
observed in cirrhosis [10].
In the last few years progresses have been realized in the identiﬁca-
tion of different enzymes involved in PAF remodeling during inﬂamma-
tion. Indeed, four different acyltransferase (LPCAT 1–4) isoforms have
been recognized to be involved in this pathway [16–20]. Despite the
large interest on these ﬁndings, the role of LPCAT during pathological
conditions remains still unknown.
Silybin, the main constituent of milk thistle extract, has been shown
to have hepatoprotective effects in several in vitro and animal models
[32–34] and to inhibit the hepatic production of pro-inﬂammatory
and pro-ﬁbrogenic factors [35].
The present study was addressed to dissect the molecular
mechanisms underlying the increased PAF level in cirrhotic liver
pointing out the role of LPCAT pathways. The molecular mechanism of
the antiinﬂammatory effect of silybin in cirrhotic liver was also
investigated.
Fig. 5. LPCAT1 and LPCAT2 protein levels. Proteins from microsomal fractions were
separated by gel electrophoresis. After transfer on a nitrocellulose paper, ﬁlters were
incubated with LPCAT1 and LPCAT2 antibodies. Band intensity corresponding to recog-
nized proteins was quantiﬁed by densitometric analysis. Signals were normalized with
alpha-tubulin.
Fig. 7. Liver lyso-PAF acetyltransferase activity. Liver homogenate from control (SHAM),
cirrhotic (BDL) and cirrhotic rats treated with silybin (BDL + Sil) were used for the
assay. The enzymatic activity was measured as [14C]acetyl-CoA incorporation into
lyso-PAF to form PAF. Data shown are the means ± SD of four different experiments.
Fig. 6. LPCAT1 and LPCAT2 lyso-PAF acyltransferase activities. Lyso-PAF acyltransferase
activity was measured in liver microsomal fractions from control (SHAM) cirrhotic
(BDL) and cirrhotic rats treatedwith silybin (BDL + Sil). A) LPCAT1 acyltransferase activ-
ity was measured by following the incorporation of [14C]oleoyl-CoA (18:1) or [14C]
palmitoyl-CoA (16:0) into lyso-PAF to form alkyl-PC (B) acyltransferase activity of
LPCAT2 was followed using [14C]arachidonyl-CoA as acyl-CoA donors. Results are the
means ± SD of four different experiments.
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cellular membranes and then the main substrate for the production of
lysophospholipids following breakdown of sn-2 bond by PLA2 activity.
Accordingly to [10,36] an increased level of both lyso-PAF and PAF
was found in the liver of BDLwith respect to control animals. Moreover,
silybin treatment signiﬁcantly decreased the BDL liver level of both
proinﬂammatory lipids bringing to values even lower than controls.
We then supposed a regulation by silybin on PLA2 activity. In our exper-
iments, in agreement with [31], an increase in the PLA2 activity was
measured in the livers of BDL compared to control rats (Fig. 3). Al-
though silybin had a moderate resetting effect of PLA2 activity (Fig. 3)
we considered this not enough to lead lyso-PAF to such low values as
we measured. We then hypothesize another mechanisms involved in
the increased PAF and lyso-PAF levels in BDL liver.
Previous observations reported that LPCAT enzymes are able to re-
model membrane phospholipids during inﬂammation [37]. Among
the four LPCAT isoforms so far studied, LPCAT1 and LPCAT2 are the
well deﬁned. A major liver LPCAT isoform, named LPCAT3, has been
recently characterized [20,38] which is structurally different from
other members of the glycerolipid acyltransferase family [39].
In our study the amount of LPCAT1–2mRNAwas drastically reduced
in cirrhotic as compared to the control livers, while the inhibitory effect
was less evident on LPCAT3. Interestingly, treatment of cirrhotic ani-
mals with silybin almost completely restored the mRNA levels of
LPCAT1 and LPCAT2 but not of LPCAT3 (Fig. 4). We then speculated
that the expression of LPCAT3 is under a differentmechanism of regula-
tion than LPCAT1–2. In fact, in a recent report, a different response toﬁbrate administration was observed for LPCAT1 and LPCAT2 as com-
pared to LPCAT3 and LPCAT4 [40]. Further studies should be encouraged
to better identify the promoter structures of these enzymes in order to
explain the response to silybin.We should take into account that silybin
Fig. 8. Schematic representation of PAF synthesis and remodeling during cirrhosis. In liver cirrhosis membrane alkyl-PC is hydrolyzed, by activated cytoplasmic PLA2, in lyso-PAF. This
latter is converted to PAF by lyso-PAF acetyltransferase (Lyso-PAF-AT) whose activity in increased in cirrhotic liver. Activity and expression of both LPCAT1 and LPCAT2 isoforms were
down-regulated under this condition, as highlighted by dashed lines. Silybin treatment, activating both LPCAT1 and LPCAT2 enzymes, subtracted lyso-PAF to acetyltransferase reaction,
to form alkyl-PC, thus decreasing liver PAF synthesis.
2025E. Stanca et al. / Biochimica et Biophysica Acta 1832 (2013) 2019–2026also inhibitsNF-kB activation [23] beingNF-kB a transcription factor im-
plicated in inﬂammatory pathway PAF-mediated [41].
The analysis of LPCAT protein level conﬁrmed the gene expression
results thus strengthening our hypothesis for a speciﬁc control, by
these enzymes, on liver PAF level.
To understand the LPCAT contribution in PAF synthesis during cir-
rhosis the activity of both LPCAT1 and LPCAT2 was measured.
LPCAT1 plays an essential role in alveolar type II cells in produc-
tion of dipalmitoyl-PC, the major phosphatidylcholine in pulmonary
surfactant [18,26]. Furthermore, an antiinﬂammatory role to LPACT1
in diabetic rats has been demonstrated [5]. This effect was attributed
to the capacity of LPCAT1 to catalyze acyl-CoA transfer to lyso-PAF
thus generating alkyl-PC, an inactive form of PAF. The acyltransferase
activity of LPCAT1 expressed in CHO-K1 cells has been demonstrated
to be speciﬁc for saturated fatty acids [17] and palmitoyl-CoA was
used to kinetically characterize the acyltransferase of LPCAT1 [18].
In COS-7 cells LPCAT1 was also demonstrated to efﬁciently catalyzed
oleoyl transfer into lyso-PAF [5]. Moreover, in murine model, LPCAT1
is able to catalyze the synthesis of physiological doses of PAF [26]. The
acetyltransferase activity of LPCAT1 is non-inducible, Ca++ indepen-
dent and needs high acetyl-CoA concentrations [26].
LPCAT2mayhave both acetyltransferase and arachidonyltransferase
activities [19] but, contrary to LPCAT1, both acyl- and acetyltransferase
activities of LPCAT2 require Ca++. Moreover, the acetyltransferase ac-
tivity of LPCAT2 was induced under inﬂammatory stimulus [19].
In the liver of cirrhotic rats we found a strong decrease in
acyltransferase activity, associated with both LPCAT1 and LPCAT2
(Fig. 6). The acyltransferase activities were reported almost to control
values following silybin treatment. The fact that the changes of activity
were the same as those seen for the mRNA reinforced our idea that the
acyltransferase activities measured were identiﬁed in LPCAT1 and
LPCAT2.
Since values of LPCAT acyltransferase activities were roughly of
the same order of magnitude of the amount of inﬂammatory lipids
(Fig. 2) we may suggest that the increased amount of lyso-PAF and
PAF in cirrhotic liver could be almost in part due to a decreased
LPCAT1 and LPCAT2 acyltransferase activities.
In good agree with previous data from Harayama et al. [17] LPCAT1
acetyltransferase activity resulted practically undetectable in all liver
microsomal samples whereas the acetyltransferase activity associated
to LPCAT2 was barely detectable in the three groups of animals.
On the other hand, acetyltransferase activity was found to increase
in the whole homogenate from cirrhotic liver as compared to controls
by using the protocol reported in [27] avoiding Ca++ and a pH inap-
propriate for LPCAT acetyltransferase activities [17]. Thus we can sup-
port the suggestion that the activity measured became from otheracetyltransferase forms. In any cases silybin was not able to affect
the acetyltransferase activity in cirrhotic livers (Fig. 7).5. Conclusions
To our knowledge, our results demonstrated that both LPCAT1 and
LPCAT2 act as acyltransferase enzymes in cirrhotic livers and a novel
mechanism for the antiinﬂammatory effect of silybin during cirrhosis
development giving its ability to decrease both lyso-PAF and PAF
levels. Moreover we also demonstrated that, almost in cirrhotic ani-
mals, silybin regulates acyltransferase activity by elevating the ex-
pression of genes encoding for LPCAT1 and LPCAT2.
Fig. 8 depicts, in a schematic way, the role of LPCAT enzyme in
liver cirrhosis. Silybin restoring the acyltransferase activity of two
LPCAT enzymes reduces the amount of lyso-PAF available for the syn-
thesis of PAF.
Although further studies are required to better understand the role
of silybin in the modulation of LPCAT in liver inﬂammation and regen-
eration, these data provide new insights into the antiinﬂammatory
mechanism of silybin in chronic liver diseases.References
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